{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:57:57Z","timestamp":1760014677952},"reference-count":94,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2016,2,28]]},"DOI":"10.2217\/fon.15.342","type":"journal-article","created":{"date-parts":[[2016,1,13]],"date-time":"2016-01-13T11:34:21Z","timestamp":1452684861000},"page":"477-491","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":7,"title":["Ibrutinib for Mantle Cell Lymphoma"],"prefix":"10.1080","volume":"12","author":[{"given":"David L","family":"Tucker","sequence":"first","affiliation":[{"name":"Department of Haematology, Plymouth Hospitals NHS Trust, Plymouth, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon A","family":"Rule","sequence":"additional","affiliation":[{"name":"Department of Haematology, Plymouth Hospitals NHS Trust, Plymouth, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2016,1,13]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23608"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2508"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08228.x"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13000"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-370320"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-521898"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2004.04.008"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.85"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00741.x"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.3109\/08830185.2012.664797"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2230"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3456"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1383"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-06-1864"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-011-0019-7"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29326"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/2162-3619-2-4"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05883.x"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-3215"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.019745"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-424630"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2013.07.028"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-482125"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.040659"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-185827"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08638"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.9.6.722"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/0952-7915(94)90151-1"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2000.imr017504.x"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1155\/2001\/28962"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.1046"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.200600221"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.9665"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.7977"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.2835"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-013-0188-8"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V122.21.4397.4397"},{"key":"e_1_3_2_42_1","volume-title":"56th ASH Annual Meeting and Exposition","author":"Rajasekeran N","year":"2014","unstructured":"Rajasekeran N , SadaramM, HebbJet al. Three BTK-specific inhibitors, in contrast to ibrutinib, do not antagonise rituximab-dependent NK-cell mediated cytotoxicity. Presented at: 56th ASH Annual Meeting and Exposition. San Francisco, CA, USA, 6\u20139 December 2014."},{"key":"e_1_3_2_43_1","unstructured":"Indications and usage IMBRUVICA \u2013 full prescribing information. Pharmacyclics Inc. Ref. ID 3395788 (2013). www.janssenmd.com\/pdf\/imbruvica\/PI-Imbruvica.pdf."},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1004594107"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12895"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.777837"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2012.09.008"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-548610"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2867-14-32"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.7906"},{"key":"e_1_3_2_51_1","volume-title":"53rd ASH Annual Meeting and Exposition","author":"Zhang L","year":"2011","unstructured":"Zhang L , QianJ, OuZet al. Carfilzomib, an irreversible proteosome inhibitor, induces long-term growth inhibition of MCL in vivo. Presented at: 53rd ASH Annual Meeting and Exposition. San Diego, CA, USA, 10\u201313 December 2011."},{"key":"e_1_3_2_52_1","volume-title":"American Society of Hematology Meeting 2011","author":"Ponada S","year":"2011","unstructured":"Ponada S , BalasubramanianS, PhamLV, ChenJ. Activity of Bruton\u2019s tyrosine kinase (Btk) inhibitor PCI-32765 in mantle cell lymphoma (MCL) identifies Btk as a novel therapeutic target. Presented at: American Society of Hematology Meeting 2011. San Diego, CA, USA, 10\u201313 December 2011."},{"key":"e_1_3_2_53_1","volume-title":"55th ASH Annual Meeting and Exposition","author":"Ou Z","year":"2013","unstructured":"Ou Z , PhamL, VangMet al. Targeting BCR-activated STAT-3 by ibrutinib in mantle cell lymphoma. Presented at: 55th ASH Annual Meeting and Exposition. New Orleans, LA, USA, 7\u201310 December 2013."},{"key":"e_1_3_2_54_1","volume-title":"55th ASH Annual Meeting and Exposition","author":"Brett LK","year":"2013","unstructured":"Brett LK , AxelrodM, OuZet al. Drug screening reveals that ibrutinib (PCI-32765) exhibits synergy with BCL-2 and proteosome inhibitors in models of mantle cell lymphoma and chronic lymphocytic leukemia. Presented at: 55th ASH Annual Meeting and Exposition. New Orleans, LA, USA, 7\u201310 December 2013."},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12206"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13149"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2013-2432"},{"key":"e_1_3_2_58_1","volume-title":"56th ASH Annual Meeting and Exposition","author":"Zhang L","year":"2014","unstructured":"Zhang L , ZhangH, ZhaoDet al. Anti-CD20 and B-cell receptor-mediated growth inhibition and apoptosis: a preclinical study of ibrutinib and rituximab combination therapy in mantle cell lymphoma in vitro and in vivo. Presented at: 56th ASH Annual Meeting and Exposition. San Francisco, CA, USA, 6\u20139 December 2014."},{"key":"e_1_3_2_59_1","volume-title":"54th ASH Annual Meeting and Exposition","author":"Sahakian E","year":"2012","unstructured":"Sahakian E , Rock-KlotzJ, ShahBet al. Combination of ACEY1215, a selective histone deacetylase 6 (HDAC6) inhibitor with the Bruton tyrosine kinase (BTK) inhibitor, ibrutinib, represents a novel therapeutic strategy in mantle cell lymphoma (MCL). Presented at: 54th ASH Annual Meeting and Exposition. Atlanta, GA, USA, 8\u201311 December 2012."},{"key":"e_1_3_2_60_1","volume-title":"56th ASH Annual Meeting and Exposition","author":"Tabe Y","year":"2014","unstructured":"Tabe Y , HaradaM, MiyamaeYet al. Selective inhibitor of nuclear export selinexor (KPT-330) and BCL2 inhibitor ABT-199 enhance the anti-lymphoma effect of btk inhibitor ibrutinib in mantle cell lymphoma. Presented at: 56th ASH Annual Meeting and Exposition. San Francisco, CA, USA, 6\u20139 December 2014."},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-390989"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-386417"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23880"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-635326"},{"key":"e_1_3_2_65_1","volume-title":"56th ASH Annual Meeting and Exposition","author":"Wang M","year":"2014","unstructured":"Wang M , HagemeisterF, WestinJRet al. Ibrutinib and rituximab are an efficacious and safe combination in relapsed mantle cell lymphoma: preliminary results from a Phase II clinical trial. Presented at: 56th ASH Annual Meeting and Exposition. San Francisco, CA, USA, 6\u20139 December 2014."},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-597914"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70311-0"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-619163"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08315.x"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-523845"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24518"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404511"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70200-0"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12008"},{"key":"e_1_3_2_75_1","volume-title":"56th ASH Annual Meeting and Exposition","author":"Christian B","year":"2014","unstructured":"Christian B , KuruvillaJ, SmithSMet al. A Phase I study of ibrutinib and lenalidomide in patients with relapsed and refractory B-cell non-Hodgkin\u2019s lymphoma. Presented at: 56th ASH Annual Meeting and Exposition. San Francisco, CA, USA, 6\u20139 December 2014."},{"key":"e_1_3_2_76_1","first-page":"1","article-title":"The use of Bruton\u2019s tyrosine kinase inhibition as a bridging strategy to successful allogeneic stem cell transplant in relapsed mantle cell lymphoma","volume":"19","author":"Furtado MV","year":"2015","unstructured":"Furtado MV , ClarkeK, MeddP, HunterH, RuleSAJ. The use of Bruton\u2019s tyrosine kinase inhibition as a bridging strategy to successful allogeneic stem cell transplant in relapsed mantle cell lymphoma. Leuk. Lymphoma19, 1\u20132 (2015).","journal-title":"Leuk. Lymphoma"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05716.x"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22715"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt139"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.MP.0000030088.28684.5B"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm447"},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.3.941"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050491"},{"key":"e_1_3_2_84_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-05-647834"},{"key":"e_1_3_2_85_1","volume-title":"56th ASH Annual Meeting and Exposition","author":"Herman SEM","year":"2014","unstructured":"Herman SEM , MustafaRZ, FarooquiMZH, WiestnerA. In vivo ibrutinib abrogates BCR-dependent adhesion in tumor cells of patients with chronic lymphocytic leukemia. Presented at: 56th ASH Annual Meeting and Exposition. San Francisco, CA, USA, 6\u20139 December 2014."},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-527853"},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400376"},{"key":"e_1_3_2_88_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"e_1_3_2_89_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-583294"},{"key":"e_1_3_2_90_1","first-page":"1","article-title":"Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation","volume":"2014","author":"Kamel S","year":"2014","unstructured":"Kamel S , HortonL, YsebaertLet al. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia2014, 1\u20135 (2014).","journal-title":"Leukemia"},{"key":"e_1_3_2_91_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0091042"},{"key":"e_1_3_2_92_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400029"},{"key":"e_1_3_2_93_1","first-page":"S35","article-title":"Ibrutinib naive chronic lymphocytic leukemia lacks Bruton\u2019s tyrosine kinase mutations associated with treatment resistance","volume":"99","author":"Rasi S","year":"2014","unstructured":"Rasi S , FarnaR, BombenRet al. Ibrutinib naive chronic lymphocytic leukemia lacks Bruton\u2019s tyrosine kinase mutations associated with treatment resistance. Haematologica99, S35 (2014).","journal-title":"Haematologica"},{"key":"e_1_3_2_94_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12974"},{"key":"e_1_3_2_95_1","volume-title":"56th ASH Annual Meeting and Exposition","author":"Balasubramanian S","year":"2014","unstructured":"Balasubramanian S , SchafferM, WilliamD Mutational analysis of patients with primary resistance to single-agent ibrutinib in relapsed or refractory mantle cell lymphoma (MCL). Presented at: 56th ASH Annual Meeting and Exposition. San Francisco, CA, USA, 6\u20139 December 2014."},{"key":"e_1_3_2_96_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv111"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon.15.342","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:45:56Z","timestamp":1719125156000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon.15.342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,13]]},"references-count":94,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,2,28]]}},"alternative-id":["10.2217\/fon.15.342"],"URL":"https:\/\/doi.org\/10.2217\/fon.15.342","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,13]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-10-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-12-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-01-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}